Quarterly report [Sections 13 or 15(d)]

Asset Purchase and Merger Agreements - Urica Agreement with Crystalys Therapeutics, Inc. ("Crystalys") (Details)

v3.26.3
Asset Purchase and Merger Agreements - Urica Agreement with Crystalys Therapeutics, Inc. ("Crystalys") (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Jul. 31, 2024
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Dec. 31, 2025
Asset Purchase and Merger Agreements            
Royalty revenue   $ 234 $ 606 $ 1,229 $ 2,010  
Urica            
Asset Purchase and Merger Agreements            
Percentage of equity to be held 35.00%          
Increase in fair value of investment due to anti-dilutive shares received       3,200    
Increase in fair value due to equity financing       8,600    
Royalty revenue   $ 0   $ 11,800    
Other income from reversal of repurchase option liability           $ 2,600
Urica | Asset Purchase, Royalty And Related Agreements With Crystalis            
Asset Purchase and Merger Agreements            
Consideration transferred $ 6,400          
Recorded accretion     $ 700   $ 1,300  
Urica | Crystalys Therapeutics, Inc            
Asset Purchase and Merger Agreements            
Required minimum ownership (as a percent)   9.00%   9.00%    
Percentage of royalty on future net sales 3.00%          
Royalty revenue       $ 0    
Urica | Crystalys Therapeutics, Inc | Minimum            
Asset Purchase and Merger Agreements            
Required minimum ownership (as a percent) 15.00%